Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07441460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Name: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer — clinical trial record (NCT07441460)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorShanghai JMT-Bio Inc.

Started2026-03-06

View on ClinicalTrials.gov ↗

Amendment history

2026-04-02

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-03-07→confirmed 2026-03-06

Study sites0→1

2026-02-26

Original filing

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.

Trial Details

NCT Number	NCT07441460
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Resectable HER2-positive Breast Cancer
Enrollment	1,800 participants
Start Date	2026-03-06
Primary Completion	2034-08-07 (estimated)
Study Completion	2035-08-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-08